Statins May Prime the Immune System Against Ovarian Cancer, New Preprint Suggests

Researchers led by Juliane Liberto and Tian-Li Wang first confirmed in TriNetX, a large U.S. health-records network, that ovarian cancer patients on daily statins tend to live longer (the summary reports no exact figures). They then tested atorvastatin in mice with ascites-forming ovarian tumors — the fluid-borne spread typical of this cancer — using doses comparable to human prescriptions, unlike the unrealistically high doses common in earlier lab work.

Treated mice lived longer, and their tumors showed a busier immune environment: more activated CD8+ T cells (the immune cells that directly kill cancer), more M1-like macrophages (immune cells switched into tumor-fighting mode), stronger IL-15 signaling (a molecule that stimulates immune cells), and more tertiary lymphoid structures — organized clusters of immune cells inside metastatic tumor tissue.

The authors' take: daily statins may keep the immune system in a more activated state, producing the long-term survival benefit seen in population studies. This is bench evidence, not a clinical recommendation. For context, atorvastatin already features in the Care Oncology Protocol, which already includes atorvastatin; for this cancer type, see fenbendazole ovarian cancer research; for dosing discussions, our dosing calculator.

References

1. Liberto JM, Qi S, Rana MM, Shih I-M, Wang T-L. Targeting Tumor Immunity: Statins as a Repurposed Strategy for Preventing Ovarian Cancer Advancement. bioRxiv (preprint, not peer-reviewed). 2026 Sep 16. doi:10.64898/2026.09.14.751179. PMID: 42779940.

Medical Disclaimer

This article is for informational purposes only and is not medical advice. The study described is a preprint (not peer-reviewed) combining health-record analysis with animal experiments — not a clinical trial. Never start, stop or change any medication without consulting a licensed healthcare provider.